Injection of MSC303
Small molecule
Injection of MSC303 is one of 10 small molecule programs targeting Glomerular Disease. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Glomerular Disease
#DrugCompanyPhaseTrials
1Vanrafia
NovartisPhase 2
Filspari
TTravere Therapeutics, Inc.
Phase 2
Povetacicept
Vertex PharmaceuticalsPhase 2
Atacicept
EMD SeronoPhase 2
Beraprost
AstellasPhase 2
Medrol
PfizerPreclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Rayos
RRoxane Laboratories
Preclinical
Methylprednisolone, Prednisone
Bristol-Myers SquibbPreclinical
Injection of MSC303
SShanghai Changzheng Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Injection of MSC303. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- SShanghai Changzheng Hospital